Program
belantamab
Also written as “Belantamab”, “Belantamab SC” and “Belantamab IV”.
In GlaxoSmithKline's pipeline, B-cell maturation antigen binder
. Its studies are mostly in Multiple Myeloma · Autoimmune Diseases, led by GlaxoSmithKline.
Furthest: phase 2, since Jan 27, 20233 company-led studies, 2 open or runningNext primary completion: Aug 5, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 32 open or running | phase 2since Jan 27, 2023 | Jan 27, 2023 | Aug 5, 2027phase 1 · NCT07742527 |
- Named in GlaxoSmithKline’s own pipeline as
belantamab GSK2857914
, phase 1, as of Sep 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 27, 2023First study: phase 2 study in Multiple MyelomaFirst studyNCT05714839 · 123 planned · United States, Argentina, Australia and more
- May 9, 2024Phase 1 study in Autoimmune DiseasesNCT06413511
- Jul 29, 2026Phase 1 study in Multiple MyelomaNCT07742527 · 22 planned
Ahead
- Aug 5, 2027Primary completion: phase 1 study in Multiple MyelomaNCT07742527
- Aug 3, 2028Primary completion: phase 2 study in Multiple MyelomaNCT05714839
TargetBeta
“B-cell maturation antigen binder”the company's pipeline, read by Claude · source
Other programs on TNFRSF17
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| elranatamabrule | Pfizer | phase 4 | 15 |
| linvoseltamabrule | Regeneron Pharmaceuticals | phase 4 | 13 |
| teclistamabrule | Johnson & Johnson | phase 4 | 11 |
| belantamab mafodotinrule | GlaxoSmithKline | phase 3 | 25 |
| Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F | AstraZeneca | phase 3 | 12 |
| etentamig | AbbVie | phase 3 | 11 |
| ramantamig | Johnson & Johnson | phase 3 | 7 |
| anitocabtagene autoleucelrule | Gilead Sciences | phase 3 | 6 |
| equecabtagene autoleucelrule | nanjing-iaso-biotechnology-co-ltd | phase 3 | 5 |
| Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934 | Sino Biopharmaceutical | phase 3 | 4 |
| GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003rule | Innovent Biologics | phase 3 | 4 |
| Evarucabgene Autoleucelrule | nexcella-inc | phase 3 | 2 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07742527Multiple Myeloma | 1 | Not yet recruiting | Aug 5, 2027 | 22 |
| NCT06413511Autoimmune Diseases | 1 | Withdrawn | Jul 8, 2025 | 0 |
| NCT05714839Multiple Myeloma · United States, Argentina, Australia and more | 2 | Recruiting | Aug 3, 2028 | 123 |
How it is read
Names in the registry
- “Belantamab”, 2 entries
- “Belantamab SC”, 1 entry
- “Belantamab IV”, 1 entry
Conditions, from the studies’ own filings
- Multiple Myeloma, 2 studies
- Autoimmune Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.